Hemodiyaliz hastalarında hepatit C virus antikoru prevelansı: Kan transfüzyonları sayısı ve diyaliz süresinin etkileri

Prevalance of hepatitis-C virus anti-body in hemodialysis patients: Effects of blood transfusions and dialysis duration

Özet

Bu çalışmanın amacı, hemodiyaliz (HD) programındaki kronik böbrek yetmezlikli olgularda, anti-HCV prevalansını tespit ederek, buna kan transfüzyonları ve hemodiyaliz süresinin etkisini incelemek; ayrıca, anti-HCV pozitif ve negatif hastalar arasında serum alanin transferaz (ALT) düzeyleri yönünden farklılık olup olmadığını araştırmaktır. Anti-HCV, enzim immunoassay (EIA, Murex anti-HCV) yöntemiyle ölçüldü. Toplam 194 (102 erkek ve 92 kadın) olgunun 82'sinde (% 42) anti-HCV pozitif bulundu. HD' ye giriş süresi 12 aydan fazla olanlarda anti-HCV pozitifliği % 50 iken, 12 aydan az olanlarda ise % 22 olarak bulundu (p

Abstract

The aim of this study is to detect the prevalance of anti-HCV in HD cases with chronic renal failure and to investigate the effects of blood transfusions and dialysis duration on the prevalance. In this study, the prevalance of anti-HCV in HD cases with chronic renal failure and the effects of blood transfusions and dialysis duration on the prevalance and the difference in terms of serum alanine aminotransferase (ALT) levels between the groups of anti-HCV positive and negative patients were investigated. Anti-HCV measurements in all cases were performed by second generation EIA (Murex anti-HCV) method. The prevalance of anti-HCV was found out as 42 % (in 82 of 194 patients). Anti-HCV positivity was detected in 70 of 139 cases (50 %) whose dialysis duration was more than 12 months and, 12 of 55 (22 %) whose dialysis duration less than 12 months (p